German biotech BioNTech today announced that the US Food and Drug Administration (FDA) has granted fast track designation to ...

Set for multiple late-stage readouts in oncology in 2026, BioNTech is entering a crucial phase of its roadmap beyond Covid-19 ...

BioNTech (BNTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

With a broad, strategic suite of programs, Goldman Sachs views BioNTech as “being at the nexus of significant developments ...

A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the ...

BioNTech (NASDAQ:BNTX) used a presentation and question-and-answer session at the J.P. Morgan Healthcare Conference to ...

BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and ...

BioNTech has established a diversified oncology portfolio including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, comprising ADCs and cell therapies, to ...

BioNTech SE (NASDAQ:BNTX) on Thursday agreed to acquire CureVac N.V. (NASDAQ:CVAC) in an all-stock transaction. According to the agreement, shareholders can exchange CureVac shares for around $5.46 in ...

BioNTech maintains strong cash reserves (€15.85B) despite widening losses as COVID revenues decline and R&D expenses increase. BNT327 (PD-L1/VEGF-A bispecific) advances to Phase 3 trials, but shares ...

Filed in a Delaware federal court, the lawsuits claim the companies copied technology developed by Bayer's subsidiary, Monsanto, in the 1980s. This pioneering work, originally designed to strengthen ...